Iron oxide nanoparticle m-PEG-silane - Megapro Biomedical Company

Alternative Names: MPB-1523

Latest Information Update: 18 Mar 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Megapro Biomedical Company
Class Antineoplastics; Contrast media; Ferric compounds; Iron compounds; Oxides; Polyethylene glycols
Mechanism of Action Magnetic resonance imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

18 Mar 2021 Iron oxide nanoparticle m-PEG-silane is still in phase II trials for Iron deficiency anaemia in USA (MegaPro Biomedical pipeline, March 2021)
18 Mar 2021 Iron oxide nanoparticle m-PEG-silane is still in phase II trials for Liver Cancer in Taiwan (MegaPro Biomedical pipeline, March 2021)
30 Oct 2020 MegaPro Biomedical completes a phase II clinical trial in Liver cancer (Diagnosis) in Taiwan (IV) (NCT03407495)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com